Merck & Co., Inc. stock (US58933Y1055): Key cancer franchise drives outlook after latest Keytruda update

Merck & Co., Inc. remains in focus after a recent oncology update around its blockbuster cancer drug Keytruda and ongoing pipeline news. How the pharma group makes its money, where the risks lie – and what matters for US investors now.

Merck & Co., Inc. is again drawing investor attention after a fresh update on its cancer franchise and continued news flow around its immuno-oncology backbone therapy Keytruda. Recent clinical and regulatory milestones underline how central oncology has become for the US pharma group’s long-term growth ambitions, according to company communications and sector media reports. For stock market participants in the United States, Merck’s shares are a core large cap in the healthcare segment, with sentiment closely linked to the performance and patent outlook of Keytruda and the broader late-stage pipeline, as highlighted in recent coverage by major financial outlets.

In mid?2026, Merck reported further data from ongoing trials evaluating Keytruda combinations in earlier lines of treatment and across different tumor types, underscoring the company’s strategy to extend the life cycle of its flagship product. According to company statements and specialist oncology media reports, these studies aim to support additional label expansions and help offset the long?term impact of potential biosimilar competition later in the decade. The company also continues to emphasize the role of its vaccines and animal health businesses as additional earnings pillars, though oncology remains the main driver for investor narratives in the near term.

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biopharmaceuticals and animal health
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription medicines, vaccines and animal health with strong presence in the US and Europe
• Key revenue drivers: Oncology (Keytruda), vaccines and animal health products
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is a global healthcare company whose core business revolves around researching, developing, manufacturing and marketing prescription medicines, vaccines and animal health products. The group focuses on serious and chronic diseases where it believes differentiated innovation can translate into both medical value and sustainable revenue streams. In its prescription medicines portfolio, oncology has become increasingly dominant, supported by the blockbuster immunotherapy Keytruda and other pipeline assets. Simultaneously, the company maintains sizeable businesses in vaccines and hospital acute care products, which contribute to diversification across therapeutic areas.

On the human health side, Merck’s strategy combines internal research capabilities with external deals and partnerships to secure a steady flow of new product candidates. The company invests billions of dollars annually into R&D, according to its financial reports for recent fiscal years, with spending directed toward oncology, vaccines, cardiometabolic diseases, and infectious diseases, among others. By pairing its own discovery platforms with targeted acquisitions and licensing arrangements, Merck aims to strengthen its late?stage pipeline and prepare for future loss of exclusivity events. For investors, this R&D intensity is a double?edged sword: it supports potential future growth but also requires continuous cash allocation and carries inherent development risk.

Beyond human prescription drugs, Merck operates a significant animal health division, which supplies vaccines, pharmaceutical treatments, and monitoring technologies for livestock and companion animals. This business provides a complementary revenue stream that tends to show different cyclicality compared with human pharmaceuticals, often linked to global protein demand and pet health trends. Animal health has also proven relatively resilient in past macroeconomic slowdowns, giving the group an additional buffer when other segments face pricing pressure or reimbursement changes. Together, these segments help Merck maintain a diversified earnings profile within the broader healthcare ecosystem.

Historically, Merck has also used portfolio optimization to sharpen its strategic focus. In previous years, the company separated certain mature brands and women’s health assets into a standalone entity, allowing the core group to concentrate capital and management resources on faster?growing and R&D?intensive businesses. This approach is in line with a broader industry trend where large pharma companies streamline non?core portfolios to improve growth and margin profiles. From a capital markets perspective, such moves are closely watched as they can influence reported revenue mix, growth rates, and valuation multiples over time. For US?listed Merck shares, the emphasis is now squarely on innovation?driven areas.

Main revenue and product drivers for Merck & Co., Inc.

The single most important product for Merck today is the cancer immunotherapy Keytruda, which has delivered multi?billion?dollar annual revenues in recent years. According to the company’s latest available annual report, Keytruda sales have grown strongly year over year, supported by new indications and broader adoption across tumor types and treatment lines. The therapy is approved for various cancers, including melanoma, non?small cell lung cancer and several other tumor entities, often in combination with chemotherapy or other agents. This breadth of indications has made Keytruda a central pillar of Merck’s earnings profile and a key determinant for investor expectations.

Recent news around Merck has largely focused on further expanding the scientific and commercial footprint of Keytruda. The company has reported new clinical trial readouts and regulatory milestones aimed at moving the drug into earlier stages of cancer treatment or into new tumor indications. For example, in early 2026 Merck highlighted data in additional solid tumors that could potentially support label expansions in major markets if regulators agree. Each successful expansion can extend the product’s growth trajectory and help offset the eventual impact of patent expirations later in the decade, an issue that market participants monitor closely.

Beyond Keytruda, Merck generates substantial revenue from its vaccines portfolio. The human papillomavirus (HPV) vaccine line, particularly Gardasil, has been a strong contributor, driven by public health programs and increasing awareness of HPV?related cancer risks. In the company’s recent financial disclosures, vaccine sales have shown robust demand in multiple regions, including the United States, Europe and parts of Asia. Seasonal and pediatric vaccines further complement this portfolio, providing recurring revenue that can be less sensitive to economic cycles than some other healthcare products. For US investors, this vaccine franchise offers exposure to long?term public health trends and national immunization schedules.

The animal health segment is another important driver, with products that target livestock productivity, disease prevention and pet well?being. Market reports and company commentary suggest that global demand for animal health solutions continues to grow, fueled by rising consumption of animal protein and increasing spending on companion animals. Merck’s solutions in this area span vaccines, parasiticides and digital monitoring tools that allow farmers and pet owners to track animal health metrics. While smaller than the human health division, this business often delivers attractive margins and can support overall earnings stability, especially when major human medicines approach loss of exclusivity.

In hospital and specialty care, Merck markets products in areas such as acute care, infectious diseases and cardiometabolic conditions. Some of these portfolios include established medicines that generate steady, though lower?growth, revenue streams. In combination with the high?growth oncology and vaccine franchises, these products help balance the group’s overall risk profile. For investors analyzing the stock, understanding the contribution and trajectory of each segment is essential, as shifts in payer policies or competitive dynamics in one area can be partially offset by performance in others.

Conclusion

Merck & Co., Inc. remains one of the most closely watched large pharma stocks in the US market, with the Keytruda oncology franchise at the center of the investment case. Recent clinical and regulatory updates around the cancer portfolio, together with a solid vaccines and animal health base, illustrate both the company’s strengths and its dependence on a few key assets. For US investors and international market participants alike, the main questions revolve around the sustainability of Keytruda’s growth, the timing and impact of eventual patent expiries, and the ability of Merck’s pipeline and business diversification to support earnings beyond the current cycle. The stock therefore continues to embody both the upside potential and the specific risks associated with innovation?driven healthcare companies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.